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Abstract
Summary The cathepsin K inhibitor, ONO-5334, improves
bone mineral density in postmenopausal women with osteopo-
rosis. The effects of morning versus evening administration of
ONO-5334 were investigated by measuring bone turnover
marker levels in healthy postmenopausal women. Morning
administration of ONO-5334 showed a more consistent sup-
pressive effect on bone resorption than evening administration.
Introduction Bone turnover is thought to be subject to circa-
dian variation, and the efficacy of osteoporosis treatments may
be optimized by regulating the time of dosing. This study
assessed whether evening administration of the cathepsin K
inhibitor, ONO-5334, had a differential effect on the bone
turnover marker, C-terminal telopeptide of type I collagen
(CTX-I), compared with morning administration.
Methods This was a single-center, single blind crossover study.
Fourteen healthy postmenopausal women were assigned to re-
ceive ONO-5334 150 mg once daily for 5 days in each period;
they were randomized to receive either evening doses in the first
period andmorning doses in the second or vice versa. Serum and
urinary levels of CTX-I were measured throughout the study.
Results Both regimens showed similar patterns of reduction in
serum and urinary CTX-I; however, CTX-I suppressionwasmore
consistently >60% over 24 h following morning administration.
Morning administration led to 6% greater suppression of 24-h
serum CTX-I area under the effect curve (AUE; 69 vs 63%; P <
.05) and 7%greater suppression of urinary CTX-I/creatinineAUE
(93 vs 86%; P < .01) than evening administration. Higher plasma
ONO-5334 concentrations were observed between 12 and 24 h
postdose following morning administration, with mean trough
concentrations for the morning and evening regimens at 9.4 and
4.0 ng/mL, respectively. Therewere no safety findings of concern.
Conclusion Morning dosing of ONO-5334 is more effica-
cious at reducing markers of bone turnover in healthy post-
menopausal women than evening dosing.
Trial registration ClinicalTrials.gov: NCT01384188,
registered on June 27, 2011
EudraCT: 2008-006284-37
Keywords Anti-resorptive . Bone resorption .Menopause .
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Abbreviations
AUC24h Area under the concentration–time curve during
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Introduction
Osteoporosis mainly arises in postmenopausal women and
affects >10 million people in the USA; the incidence is set
to increase as the population ages [1]. Osteoporosis is charac-
terized by low bone mass disordered bone architecture, lead-
ing to an increased risk of vertebral and other fractures.
Osteoporosis is associated with significant morbidity, and
hip fractures as sequelae confer a 1-year mortality risk of
8.4–36% primarily due to thromboembolic events [1].
An important contributory factor to low bone mass in oste-
oporosis is increased bone resorption. Antiresorptive drugs
such as the bisphosphonates reduce bone resorption and are
the current drug class of choice for the prevention of fractures
in patients with osteoporosis [2]. However, bisphosphonates
are not well tolerated by many patients, may cause abdominal
discomfort or dyspepsia and are difficult to administer.
Furthermore, chronic bisphosphonate therapy may enhance
the risk of atypical femur fractures, although the overall inci-
dence of fractures is reduced [3]. Hence, there is a need to
develop novel, safe and efficacious treatments for osteoporosis.
Cathepsin K inhibitors including odanacatib [4] and ONO-
5334 are a new class of drugs against osteoporosis which are
undergoing clinical development. ONO-5334 improved bone
strength by preferentially increasing cortical bone mass in
ovariectomized rats [5] and significantly improved cortical
and trabecular bone mineral density (BMD) in postmenopausal
women with osteoporosis following 24 months of therapy [6].
In healthy postmenopausal women, ONO-5334 100 mg
sustained-release tablet (SRT) administered in the morning ex-
hibited amedian time tomaximum plasma concentration (Tmax)
of 4 h and mean half-life of 15 h following repeat administra-
tion [7, 8], suggesting the feasibility of once-daily dosing.
Serum and urinary bone turnover markers such as C-
terminal telopeptide of type I collagen (CTX-I) peak in the
early morning hours and reach nadir in the afternoon, demon-
strating that bone resorption is highest at night in healthy and
osteoporotic postmenopausal women [9–13].
Thus, evening administration of antiresorptive drugs such
as ONO-5334, in contrast to the more conventional morning
administration, is of interest because plasma drug levels may
be higher at the time when bone resorption is greatest.
The influence of administration time of anti-osteoporosis
drugs on efficacy varies. For instance, Blumsohn and co-
workers [14] administered elemental calcium 1000 mg at bed-
time, which suppressed nighttime increases of bone resorption
and reduced 24 h of excretion of bone resorption markers in
premenopausal women, whereas morning administration had
no effect. In addition, Karsdal and coworkers [15, 16] showed
that oral calcitonin given between 17:00 and 22:00 exerted
greater reductions of bone turnover markers compared with
administration at 08:00. Odanacatib is administered once
weekly, so the effects of administration time on efficacywould
be of little value; however, ONO-5334 is intended as a once-
daily medication
This study investigated healthy postmenopausal women as a
representative potential patient population with similar predom-
inant features of gender, age and hormonal milieu of patients
with osteoporosis, without the attendant concomitant treatments
that might confound the results. The aim of this randomized,
single blind, two-part crossover study was to investigate the
effects of morning versus evening administration on the phar-
macokinetics and pharmacodynamics of multiple doses of
ONO-5334 150-mg SRT in healthy postmenopausal women.
Methods
Study population
Healthy female subjects aged 55–75 years with a body mass
index of 19–30 kg/m2 were enrolled. Subjects had been amen-
orrheic for ≥5 years and had follicle-stimulating hormone >30
IU/L and estrogen <92 pmol/L. Subjects had a sleep history
(for ≥1 month before screening) of regular bedtime and sleep
duration, did not awake more than twice nightly for micturi-
tion, had no habit of daytime naps >1 h and experienced no
sleep complaint as determined by a Pittsburgh Sleep Quality
Index (PSQI) [17] score of >5. Subjects were in good health at
both screening visits between 41 and 10 days before the first
dose.
To minimize possible confounding factors of exercise and
sleep/wake (circadian) on bone turnover, exercise was restrict-
ed, and a regular sleep/wake cycle was scheduled. Subjects
maintained bedtime at 22:30 and wake-up time at 06:30
throughout the study period. This applied at home from the
second screening visit until admission to the clinical unit and
during the entire 10-day residential period. A subjective sleep
diary incorporating the Karolinska Sleepiness Scale [18] and
actigraphy (as monitored by Actiwatch AW4; Cambridge
Neurotechnology, Cambridge, UK) confirmed compliance to
the sleep/wake schedule and limited exercise regimen.
Informed consent was obtained from all individual partic-
ipants included in the study. The study was approved by a
local review board (London Westminster Research Ethics
Committee) and conducted in accordance with the
Declaration of Helsinki and GoodClinical Practice guidelines.
Study design
This was a randomized, single blind, single center, two-period
c rossove r s tudy (p ro toco l : ONO-5334POE010;
ClinicalTrials.gov: NCT01384188) between June and
December 2011 at the Surrey Clinical Research Centre, with
recruitment and initial screening performed at another site.
Subjects received a single dose of oral ONO-5334 150-mg
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SRT (Ono Pharmaceutical Co, Ltd, Osaka, Japan) once-daily
for 5 days in each treatment period.
Subjects were randomly assigned to receive evening ONO-
5334 administration in the first period and morning adminis-
tration in the second or vice versa. Randomization codes were
provided by quintiles and generated by the computer software
package Statistical Analytical System (SAS) version 9.2.
Treatment periods were separated by a washout of ≥10 days.
To maintain blinding, evening dose subjects took a placebo in
the morning and morning dose subjects took a placebo in the
evening.
All meals were standardized throughout the treatment pe-
riod with nutritionally matched morning and evening meals.
Breakfast, lunch and dinner were served at 07:00, 13:00 and
19:00, respectively. All subjects were given the same meal at
each sitting and encouraged to finish the meal. Study agents
were administered 30 min after the subjects finished morning
or evening meals, at 08:00 and 20:00, respectively. A final
follow-up visit was scheduled 5–8 days after the last dose.
Pharmacokinetic sample collection and analysis
Blood samples for measurement of plasma ONO-5334 con-
centration were collected via intravenous cannula over 12 h on
day 1 and over 24 h on day 5. Samples were taken once hourly
between 1 and 6 h postdose. Sample time-points were relative
to the ONO-5334 active dose (either morning or evening) in
each treatment period. To minimize overnight disturbance,
long-line extension tubing was attached to the cannula,
allowing sample collection in another room.
ONO-5334 was extracted from plasma samples using a
solid-phase extraction column followed by quantification.
Plasma concentrations of ONO-5334 were determined by a
validated liquid chromatography–tandem mass spectroscopy
method with a lower limit of quantification at 0.02 ng/mL.
The assay was performed by Sumika Chemical Analysis
Service (Osaka, Japan).
Pharmacokinetic parameters were estimated using
noncompartmental methods (Phoenix WinNonlin version
6.1; Pharsight, Mountain View, CA, USA) and included max-
imum observed concentration (Cmax), Tmax and area under the
concentration–time curve during the dosing interval
(AUC24h).
A scatter plot of individual plasma ONO-5334 concentra-
tions versus serum CTX-I values (% change from baseline,
defined as day −1) was produced, and a squared correlation
coefficient (R2) value was calculated. All data retrieved on
day 5 in both treatment periods were included.
Pharmacodynamic sample collection and analysis
Blood and urine samples were collected for analysis of bio-
chemical markers of bone turnover (Serum and Urine
CrossLaps ELISA; Immunodiagnostic Systems, Boldon,
UK). Baseline serum samples for CTX-I were taken via an
intravenous cannula on day −1 for the morning dosing period
at 08:00, 10:30, 14:00, 16:00, 18:00, 20:00, 22:30, 02:00,
04:00, 06:00 and then again at 08:00 just before dosing on
day 1. For the evening dosing period, sampling started at
20:00 on day −1 and then at similar intervals until 20:00 on
day 1 just before dosing. Baseline urine samples were collect-
ed on day −1 for the morning dosing period from 08:00–
10:30, 10:30–14:00, 14:00–16:00, 16:00–18:00, 18:00–
20:00, 20:00–22:30, 22:30–04:00 to 04:00–08:00. For the
evening dosing period, sampling started at 20:00 and then at
similar collection intervals until 20:00 on day 1 just before
dosing.
Serum and urine samples were taken postdose on days 1
and 5 at 08:00 for the morning dosing and 20:00 for the eve-
ning dosing. Blood samples for analysis of serum CTX-I were
taken at 2.5, 6, 8, 10, 12, 14.5, 18, 20, 22 and 24 h postdose on
days 1 and 5. Urine was collected for analysis of urinary CTX-
I over 0–2.5, 2.5–6, 6–8, 8–10, 10–12, 12–14.5, 14.5–20 and
20–24 h postdose on days 1 and 5. If subjects had not voided
urine between 22:30 and 04:00 on overnight collection days,
they were woken just before 04:00 to provide a urine sample.
A dim red light (<10 lx) minimized impact on circadian status
during scheduled lights-off periods.
Pharmacodynamic analyses were conducted by Charles
River Laboratories (Edinburgh, UK). Parameters included de-
rived total 24-h urinary CTX-I (area under the effect curve;
AUE) and derived total 24-h serum CTX-I (AUE). Urinary
CTX-I measurements were adjusted for urinary creatinine.
Safety assessments
Clinical laboratory tests, vital signs, 12-lead electrocardio-
grams and physical examinations were performed in each
treatment period on admission and at follow-up; vital signs
were measured at baseline, on all treatment days and upon
discharge. All adverse events were coded using Medical
Dictionary for Regulatory Activities version 14.1.
Statistical analysis
Pharmacodynamic and safety data were analyzed using SAS
version 9.2. Urinary and serum CTX-I data were summarized
using descriptive statistics. AUEs for urinary and serum CTX-
I were compared for morning versus evening regimens by
ANCOVA. In a post-hoc analysis, urinary and serum CTX-I
% change from clock time-matched baseline data were com-
pared for morning versus evening regimens using repeated-
measures approach.
Pharmacokinetic parameters were analyzed using SAS ver-
sion 9.1.3 and 9.2. Cmax, Tmax and AUC24h were compared
between morning and evening administration on day 5.
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Geometric mean ratios (morning/evening) and 90% CIs were
calculated using ANOVA. Tmax was analyzed by Wilcoxon
signed rank test at a two-sided significance level of 5%.
Safety data were not formally analyzed. Power calculations
are difficult to apply to circadian studies and were not per-
formed for this study. The sample size was chosen based on
the results of Blumsohn and colleagues [14].
Results
Pharmacokinetics
Eleven subjects completed the study (Table 1) and were in-
cluded on the pharmacokinetic and pharmacodynamics anal-
yses. Maximum plasma ONO-5334 levels were observed later
following evening administration than with the morning reg-
imen (Fig. 1). Mean plasma ONO-5334 concentrations were
lower between the 12- and 24-h postdose time-points on day 5
following evening administration compared with morning ad-
ministration, with mean trough concentrations of approxi-
mately 4.0 and 9.4 ng/mL, respectively. On day 5 following
morning and evening dosing, Tmax was observed at 2.0 and
5.0 h postdose, respectively (Table 2). A significant difference
in Tmax was observed between morning and evening dosing
(P = .002), although there was no significant difference
in Cmax and AUC24h.
Pharmacodynamics
On day 5, there was a marked difference between morning
versus evening dosing in serum CTX-I profile across 24 h
(time-matched against each individual’s own day −1, 24-h
baseline profile; Fig. 2a). Although evening administration
initially showed a larger suppressive effect on bone resorption,
this was not sustained over 24 h. Morning administration
showed consistent suppression on serum CTX-I across 24 h
compared with evening administration. Repeated-measures
ANCOVA of the % change from baseline for serum CTX-I
on day 5 showed a greater reduction with morning compared
with evening administration (P = .004).
Themorning dosing regimen showed a transient increase in
serum CTX-I at 8 h postdose on day 5, with levels decreasing
thereafter. Interestingly, a similar slight peak in serum CTX-I
was observed at 20 h after the evening dose, both of which
corresponded to 3 h after lunch was served.
There was a marked difference in effect between morning
and evening administration on the day 5 urinary CTX-I profile
adjusted for urinary creatinine across 24 h (time-matched
against each individual’s own day −1, 24-h baseline values;
Fig. 2b). There was a more consistent suppressive effect on
urinary CTX-I across 24 h following morning compared with
evening administration, with less suppression observed at 12 h
postdose and thereafter with the latter regimen. Repeated-
measures ANCOVA of the % change from baseline for uri-
nary CTX-I/creatinine on day 5 showed a significantly greater
reduction on morning compared with evening administration
(P = .0002).
Summarizing the data over 24 h using AUE analyses, differ-
ences betweenmorning and evening dosing appeared of a lesser
magnitude, although they retained statistical significance
(Table 3).Morning administration achieved significantly greater
Table 1 Baseline demographics: safety population
All subjects (N=14)
Enrolled, n 14
Completed, n (%) 11 (79)
Age (years), mean [SD] 65.0 (7.7)
Height (m), mean [SD] 1.63 (0.06)
Weight (kg), mean [SD] 64.6 (7.1)
Body mass index (kg/m2), mean [SD] 24.5 (2.8)
Serum CTX-I (μg/L), mean [SD]a
08:00 0.50 (0.17)
20:00 0.35 (0.09)
Total 24 h (AUE) 10.7 (2.9)
Urine CTX-I/Cr (μg/mmol Cr*h), mean [SD]a
08:00–10:30 70.5 (25.6)
20:00–22:30 69.3 (31.7)
Total 24 h (AUE) (μg/mmol Cr) 1651.9 (671.3)
All subjects were Caucasian women
SD standard deviation, CTX-I C-terminal telopeptide of type I collagen,
AUE area under the pharmacodynamic effects time curve, Cr creatinine
a Serum and urinary CTX-I weremeasured on the day before the first dose
(day −1, period 1 and period 2)
Fig. 1 Mean plasma concentration of ONO-5334 on day 5 (per protocol
set). Values are expressed as mean (SD). Mealtimes are indicated with
solid and dashed arrows for the morning and evening dosing groups,
respectively. PK pharmacokinetics, B breakfast, L lunch, D dinner
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suppression of derived total 24-h serum CTX-I (AUE) than
evening administration (P = .020). For urine-derived total
24-h CTX-I/creatinine (AUE), morning administration also
showed greater reduction than evening administration
(P = .009).
Serum CTX-I was suppressed after morning and evening
administration of ONO-5334, with lowest CTX-I levels ob-
served at 8 h postdose. Furthermore, after 24 h of dosing,
CTX-I suppression was greater in the morning group.
Figure 3 displays time-resolved CTX-I measurements after
morning (Fig. 3a) and evening (Fig. 3b) administration of
ONO-5334.
Figure 4 displays a scatter plot showing the correlation
between plasma ONO-5334 levels and extent of CTX-I sup-
pression on day 5. Data indicate that a plasma ONO-5334
concentration ≥10 ng/mL is required to produce 60% reduc-
tion of serum CTX-I.
Study population and safety
Fourteen female Caucasian subjects (mean age 65 years) were
enrolled, and 11 completed the study (Table 1). Three subjects
withdrew prematurely, two because of adverse events and one
withdrew consent after 5 days of evening administration. Two
of the three subjects withdrawn from the study were in the
morning group, and the remaining subject was in the evening
group. All three subjects had completed dosing in the first
period but were withdrawn before the second dosing period
(Supplementary Table 1). Fourteen subjects were included in
the safety analysis.
Fourteen subjects reported 79 adverse events. The most
frequent adverse event was procedural site reaction associated
with the intravenous cannula (eight subjects, 57%;
Supplementary Table 1). All adverse events resolved.
Procedural site reaction was more frequently reported after
evening administration (seven subjects [54%] compared with
four subjects [33%] after morning administration). Nausea
was more frequent after morning administration (four subjects
[33%] compared with one subject [8%] after evening
Table 2 Pharmacokinetics of
ONO-5334, day 5 (n=11) Dose (mg) Administration Cmax (ng/mL) Tmax (h) AUC24h (ng h/mL)
Mean (SD) Median [range] Mean (SD)
150 Morning 99.5 (45.3) 2.0 [1.0–3.0] 582 (196)
150 Evening 107.0 (52.0) 5.0 [2.0–6.0] 591 (204)
M/Ea (90% CI)b 0.91 (0.78–1.05) P = .0020c 0.99 (0.88–1.11)
Cmax maximum observed concentration, Tmax time to reach Cmax, AUC24h area under the concentration–time
curve during the dosing interval, SD standard deviation, M/E morning dosing/evening dosing, CI confidence
interval
a Geometric mean ratio
b 90% confidence interval of the geometric mean ratio
cWilcoxon signed rank test
Fig. 2 a Serum CTX-I (time-matched % change from baseline) after 5
days of ONO-5334 administration. Values are expressed as mean (SD).
Mealtimes are indicated with solid and dashed arrows for the morning
and evening dosing groups, respectively. CTX-I C-terminal telopeptide of
type I collagen, CFB change from baseline, B breakfast, L lunch, D
dinner. N=11. b Urinary CTX-I/creatinine (time-matched %CFB) after
5 days of ONO-5334 administration. Values are expressed as mean
(SD). Mealtimes are indicated with solid and dashed arrows for the
morning and evening dosing groups, respectively. CTX-I C-terminal
telopeptide of type I collagen, CFB change from baseline, B breakfast,
L lunch, D dinner. N=11
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administration). Of adverse events that were considered as
possibly treatment-related, nausea was most frequently report-
ed (three subjects [25%] following morning administration;
one subject [8%] following evening administration).
During the study, only one subject required concomitant
medication of E45 cream. This was for a rash on both arms
associated with cannula dressings. Two subjects were with-
drawn from treatment as a result of mild adverse events (rash
and aquagenic urticaria), considered as possibly related to
ONO-5334 treatment. The rash on the eyelids was reported
following 5 days of morning administration and resolved
without further treatment after 11 days. Following investiga-
tion, this subject had a positive anti-nuclear antibody test,
suggesting a possible autoimmune disorder. The case of
aquagenic urticaria occurred 2 days after completion of 5
days’ evening drug administration and resolved without fur-
ther treatment after 1.5 h. There were no clinically relevant
laboratory safety data, vital signs, electrocardiogram or
physical examinations.
Discussion
This study explored whether 5 days’ administration of the
novel cathepsin K inhibitor ONO-5334 150-mg SRT in the
evening, when osteoclast activity begins to rise, resulted in a
differential effect on pharmacodynamic markers of bone re-
sorption compared with morning administration. Morning ad-
ministration of ONO-5334 resulted in greater suppression of
bone resorption markers over a 24-h period than the same
Table 3 Serum and urinary CTX-I percent change from baseline on day 5 using AUE analysis over 24 h
Parameter Morning (LS Mean) Evening (LS Mean) Morning vs Evening P value
Serum CTX-I: AUE −68.8 −62.9 −5.9 0.020
Urine 24 h CTX-I/Cr: AUE −92.6 −85.8 −6.8 0.009
N=11. Analysis of covariance model including regimen, cohort, period and dosing sequence as fixed effects, baseline variable (day −1) as a covariate and
subject within sequence as a random effect
CTX-I C-terminal telopeptide of type I collagen, LS least squares, CI confidence interval, Cr creatinine, AUE area under the pharmacodynamic effects
time curve
Fig. 3 a Time course of serum CTX-I levels after morning
administration of ONO-5334 at 8:00 hours, N=12. b Time course of
serum CTX-I levels after evening administration of ONO-5334 at 20:00
hours,N=13. Filled triangle indicates predose CTX-I levels (day 1), filled
diamond indicates CTX-I levels on the day of first dosing (day 1), and
open square indicates CTX-I levels on day 5. Mealtimes are indicated
with arrows. CTX-IC-terminal telopeptide of type I collagen,B breakfast,
L lunch, D dinner
Fig. 4 Scatter plot of plasma ONO-5334 concentration versus serum
CTX-I (%CFB) on day 5. Open triangle morning dosing, filled square
evening dosing. CTX-I C-terminal telopeptide of type I collagen, CFB
change from baseline
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treatment given in the evening. These findings relate to the fed
state and with ONO-5334 150-mg administered in sustained-
release tablet formulation.
Markers of bone turnover such as serum CTX show
distinct circadian patterns [12, 13]. In women with os-
teoporosis, nocturnal serum calcium levels are sustained
by increased bone resorption, in contrast to healthy
postmenopausal women who display decreased serum
calcium and lower urinary calcium excretion during
nighttime [9]. Evening administration of antiresorptive
drugs might enhance their efficacy because drug levels
may be higher when resorption is greatest. The primary
objective of the present study was to investigate the
effects of ONO-5334 morning versus evening adminis-
tration on pharmacodynamic parameters including serum
and urinary CTX-I.
Although evening administration of ONO-5334 for 5 days
initially had a greater suppressive effect on serum CTX-I than
morning administration, this was not protracted and began to
diminish 12 h postdose (evening administration). The reduc-
tion of serum CTX-I after morning administration was more
consistent across all time-points. The urinary CTX-I profile
showed more consistent suppression across all collection
time-points following morning administration of ONO-5334.
Following evening administration, suppression of urinary
CTX-I was less apparent in urine collected ≥14 h postdose.
Post-hoc analysis demonstrated that morning administration
had significantly greater suppression of serum CTX-I and uri-
nary CTX-I/creatinine than evening administration (P < .01
and P < .001, respectively). The effect of oral calcitonin ad-
ministered in the morning, pre-dinner and in the evening on
serum CTX-I in healthy postmenopausal womenwas reported
by Karsdal et al. [15]. This showed a reduction in CTX-I, but
the results differed in two ways from the present study. The
first difference was that pre-dinner and evening doses of cal-
citonin resulted in greater CTX-I suppression than morning
dosing. Secondly, the impact on bone resorption after oral
calcitonin lasted for about 12 h, in contrast to 24 h (or more)
for ONO-5334.
The difference between morning and evening administra-
tion was less marked in AUE analyses across the 24-h period,
although significant differences were observed. Morning ad-
ministration led to 6% greater suppression of derived total
24-h serum CTX-I AUE and 7% greater suppression of de-
rived total 24-h urinary CTX-I/creatinine AUE than evening
administration. Variation between samples was low; however,
evening CTX-I levels showed highest variation, which has
been observed in previous studies [19]. Standard deviations
for the CTX-I assay employed in this study were comparable
to references of intra-individual variation [20, 21]. We consid-
ered that there may be an interaction between the effect of
feeding and the effect of the drug, but we did not find the large
decreases in CTX that are usually reported after meals
(Fig. 2a). This is likely due to the large suppression of CTX-
I by the drug.
Reductions from baseline in derived total 24-h serumCTX-
I AUE were consistent with previous reports on cathepsin K
inhibitors, balicatib and odanacatib. In postmenopausal wom-
en, serum CTX was reduced by 61% in a 1-year study on
balicatib [22] and by 62–66% following single or repeated
doses of odanacatib for 3 weeks [23, 24]. In postmenopausal
women with low BMD, once-weekly odanacatib elicited
>60% reductions of serum CTX-I for most of the first year
of treatment [25] and continuous 55% reductions were report-
ed following 5 years of treatment [4]. In the OCEAN Study,
bisphonate alendronate and ONO-5334 both exerted similar
suppressive effects on bone resorptionmarkers in womenwith
osteoporosis [26, 27]. Serum CTX-I decreases of 67–70%
were reported following 30–36 months of alendronate therapy
[28, 29], and urinary CTX-I was reduced by 53% following 12
weeks of alendronate treatment in healthy postmenopausal
women [30].
Reduction in fracture rate is the goal for prevention and
treatment of osteoporosis. An increase in BMD and suppres-
sion of bone resorption markers may achieve this. CTX-I is
the reference marker of bone resorption used to evaluate ex-
perimental osteoporosis treatments [31]. Odanacatib has
shown similar suppression of serum CTX-I to that observed
with ONO-5334 (approximately 60%), and both show clear
increases in BMD [24, 25]. Other antiresorptive agents show
similar magnitudes of serum CTX-I suppression of approxi-
mately 60–70% [32–34]. From a clinical standpoint, 60%
suppression of serum CTX-I for as long as possible following
ONO-5334 administration seems beneficial. ONO-5334 300-
mg IRT increased BMD in women with osteoporosis [26, 27]
and has shown >60% reduction from baseline in serum CTX-I
in healthy postmenopausal women [35]. Therefore, the differ-
ence in the proportion of the day when the suppressive effect
of ONO-5334 on serum CTX-I exceeded approximately 60%
in the present study (that is, across the entire 24-h period
followingmorning administration versus around half that after
evening dosing) may be clinically important.
Differences in pharmacodynamic effects between the regi-
mens in the present study were paralleled by differences in
pharmacokinetic profiles. Higher plasma ONO-5334 concen-
trations were observed between 12- and 24-h postdose follow-
ing 5 days of morning administration. This sustained plasma
concentration may explain the increased serum and urinary
CTX-I suppression observed toward the end of the 24-h peri-
od. The significantly (P = .002) later Tmax observed on day 5
after evening compared with morning dosing was considered
attributable to delayed gastric emptying in the evening com-
pared with morning [36, 37]. The disappearance rate of drug
appeared to be more rapid following evening administration;
we speculate that there may be diurnal changes in the clear-
ance rate of ONO-5334.
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In the present study, we observed a correlation between
plasma ONO-5334 levels and the extent of CTX-I suppres-
sion; our data indicate that a plasma ONO-5334 concentration
≥10 ng/mL is required to produce >60% reduction of serum
CTX-I at any given time-point.
Subjects randomized to morning administration in the first
period had significantly higher serum CTX-I before dosing in
the second period (following washout period) compared with
subjects randomized to the evening regimen in the first period.
This carryover effect may be attributed to greater suppression
during the first period, followed by a rebound effect where
CTX-I levels increased to above baseline after dosing was
stopped. Odanacatib and denosumab also show rebound ef-
fects [27, 38, 39]. To account for baseline differences, morn-
ing versus evening comparisons were performed with
(P<0.05) and without (P<0.01) adjustment for baseline, and
the results were similar. It should also be noted that baseline
bone turnover has been demonstrated to have no effect on the
efficacy of ONO-5334 [26].
Treatment-related adverse events were more frequent after
morning administration—particularly nausea, which occurred
in three of 12 subjects and one of 13 subjects following morn-
ing and evening administration. However, the sample size was
small, and the study was not powered to compare adverse
event frequency. Following 12 months of evening dosing in
285 subjects in the OCEANStudy, the adverse event profile of
ONO-5334, including nausea, was similar to placebo [26].
Procedural site reactions observed in eight subjects were re-
lated to insertion of the intravenous cannula and not to ONO-
5334 treatment per se. Two subjects were withdrawn from
treatment as a result of mild rash and aquagenic urticaria that
were considered as possibly related to ONO-5334; these did
not resemble the morphea reported with balicatib [40]. The
safety profile of ONO-5334 as regards to derangements of
connective tissue will be closely monitored in future studies.
One limitation of the study concerned blinding; the more
intensive blood and urinary sampling may have allowed sub-
jects to suspect whether they had received active study med-
ication in the morning or the evening. However, subjects were
not explicitly informed what treatments they were receiving at
the time of dosing; therefore, the study may be considered
single blind.
Women with osteoporosis have decreased bone density and
higher CTX-I levels than otherwise healthy women [41]. We
have previously shown that baseline CTX-I levels are not pre-
dictive of how patients with osteoporosis respond to
antiresorptive therapy with ONO-5334 [23]. In the same study,
we found no association between baseline BMD (in the spine
or hip) on ONO-5334 plasma levels or suppression of bone
resorption by ONO-5334 (data unpublished). This suggests
that the results of the current study on healthy postmenopausal
women may also be applied to postmenopausal osteoporotic
patients. However, one limitation is the established alteration
of circadian rhythm of bone resorption in women with osteo-
porosis, who demonstrate an approximately 15% increase
bone resorption at night relative to healthy postmenopausal
women [10]. In addition, the findings in this study relate to
the 150-mg sustained-release tablet formulation administered
in the fed state, with standardized, nutritionally matched meals.
The results may be different with other doses, formulations and
administration times of ONO-5334 and also with varied diets.
In conclusion, morning administration of ONO-5334 150-
mg SRT for 5 days conferred >60% suppression of CTX-I
sustained across 24 h, compared with 12 h after evening ad-
ministration. Morning administration achieved 6% greater
suppression of serum CTX-I 24-h AUE (P < .05) and 7%
greater suppression of urinary CTX-I/creatinine 24-h AUE
(P < .01) compared with evening administration. Despite
these differences, evening administration also appeared effi-
cacious in suppressing markers of bone resorption. Future
studies will clarify whether morning dosing would show in-
creased efficacy with regard to BMD and whether the
morning-versus-evening effect is observed with higher doses
of ONO-5334.
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